Included in the formulation
АТХ:L.01.X.X.43 Wismodegib
Pharmacodynamics:It binds to the transmembrane protein SMO, interrupting the signal transmission along the pathway of Hedgehog activation and transcription of the glioma oncogene. Prevents the proliferation and differentiation of tumor cells.
Pharmacokinetics:After ingestion, up to 30% is absorbed in the gastrointestinal tract. The connection with plasma proteins is 97%.
Metabolism in the liver.
The elimination half-life is 12 days. Elimination by the kidneys and with feces.
Indications:It is used to treat metastatic or locally advanced basal cell carcinoma in cases of relapse after surgical treatment, or if it is not appropriate, as well as radiotherapy.
II.C43-C44.C44 Other malignant neoplasms of the skin
Contraindications:Severe renal failure, individual intolerance, children under 18 years of age.
Carefully:Dysfunction of the liver, galactose intolerance, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - category X. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, regardless of food intake, 150 mg once a day.
The highest daily dose: 150 mg.
The highest single dose: 150 mg.
Side effects:Central and peripheral nervous system: asthenia, increased fatigue.
Digestive system: nausea, vomiting, anorexia, weight loss, diarrhea.
Musculoskeletal system: muscle spasms, tetany, myalgia.
Dermatological reactions: alopecia, loss of eyelashes and eyebrows, itching, rash.
Sense organs: decrease and loss of taste.
Reproductive system: amenorrhea.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:With simultaneous admission with carbamazepine, St. John's wort, rifampicin, phenytoin, the concentration of vismodegra in the blood plasma decreases.
Special instructions:Women of the reproductive period during treatment are recommended to use reliable methods of contraception during the administration of the drug and within three months after its completion.